Humanigen initiated submission for lenzilumab Marketing Authorization in COVID-19, to United Kingdomメs MHRA
On Jun. 14, 2021 Humanigen announced it had initiated a rolling review submission for Marketing Authorization (MA) by…
On Jun. 14, 2021 Humanigen announced it had initiated a rolling review submission for Marketing Authorization (MA) by…
On Jun. 8, 2021, Merck announced it had entered into a procurement agreement with the U.S. government for…
On Jun. 8, 2021, the University of Oxford announced that the RECOVERY trial found aspirin does not improve…
On Jun. 8, 2021, Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates…
On Jun. 3, 2021, Innovation Pharma announced that it had achieved full patient enrollment in its randomized, double-blind,…
On Jun. 1, 2021, the National Institutes of Health announced that it had started a Phase 1/2 clinical…
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved LUMAKRAS (sotorasib)…
On May 28, 2021, Humanigen announced that the company had submitted an application to the FDA requesting Emergency…
On May 27, 2021, Novartis and Molecular Partners announced the start of the clinical trial EMPATHY, a Phase…
On May 27, 2021, Innovation Pharma announced that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial…
On May 27, 2021, Innovation Pharmaceuticals announced that patient enrollment in the Companyメs 120-patient, Phase 2 clinical trial…
On May 21, 2021, AstraZeneca announced that it had been granted a special approval for emergency use in…
On May 20, 2021, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
On May 19, 2021, APEIRON Biologics announced the next development steps for APN01 (alunacedase alfa) for the treatment…
On May 18, 2021, GlaxoSmithKline and Medicago reported positive interim Phase 2 clinical trial safety and immunogenicity data…
On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded…
On May 5, 2021, Novavax announced the publication of results from the initial primary analysis of a Phase…
On May 5, 2021, Pfizer and BioNTech announced that Health Canada had expanded the Interim Order authorization for…
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
On Apr. 28, 2021, Innovation Pharma announced that enrollment had surpassed 50 percent of the total targeted number…
On Apr. 23, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had awarded…
On Apr. 22, 2021, the NIH announced that a phase 3 trial to test the safety and efficacy…
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
On Apr. 19, 2021, the NIH announced that it was funding a large, randomized, placebo-controlled Phase 3 clinical…
On Apr. 15, 2021, the National Institutes of Health announced that the experimental antiviral drug MK-4482 significantly decreased…
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…